SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Lidak Pharm. [LDAKA]

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: James Silverman who wrote (74)2/5/1997 2:36:00 PM
From: Jeffery Lee Funk   of 1115
 
Lidakol vs. Vasoline, If Vasoline had any effect on oral herpes then the Chesebrough Ponds Inc. would be advertising their product as the cure for oral herpes. If Lidakol is apporved it will be the first over-the-counter product available for herpes simplex virus- 1.

I think you hear rumors like this because many investors are frustrated with LDAKA stock performance and have no clinical knowledge (and I know several investors who paid > $5 a share). As I read the messages I see many investors that are way to bullish on LDAKA. The recent gains were primarly due to the January effect, 401K investing, and the increased funds in the small cap market.

The price increases were not related to the companies performance! or new products! So, if the stock continues to drop back to Nov. or Dec. price support levels do not be supprised. But I do believe that as we approach FDA approval you will see the stock move due to the rumor mill. Do keep in mind that over 50% of the product that reach stage 3 are never approved.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext